Sacubitril/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: real-world data.
ARNI
Cancer
Cardio-oncology
Cardiotoxicity
Heart failure
Natriuretic peptides
Sacubitril-valsartan
Journal
Cardio-oncology (London, England)
ISSN: 2057-3804
Titre abrégé: Cardiooncology
Pays: England
ID NLM: 101689938
Informations de publication
Date de publication:
13 Oct 2021
13 Oct 2021
Historique:
received:
01
06
2021
accepted:
07
09
2021
entrez:
14
10
2021
pubmed:
15
10
2021
medline:
15
10
2021
Statut:
epublish
Résumé
Sacubitril/valsartan has been shown to significantly reduce cardiovascular mortality and hospitalizations due to heart failure in patients with reduced ejection fraction (HFrEF) when compared to enalapril. Data about sacubitril/valsartan in patients with a history of cancer are scarce, as these patients were excluded from the pivotal trial, PARADIGM-HF. The aim of the current study was to assess tolerability of sacubitril/valsartan in patients with a history of cancer. We identified 225 patients at our heart failure out-patient unit who fulfilled the indication criteria to receive sacubitril/valsartan. Out of these, 9.3% (n = 21) had a history of histologically confirmed cancer. Oncologic surgery was performed in 16 (76.2%) patients, 11 (52.4%) patients received previous antineoplastic therapy and 9 patients (42.9%) radiation. Sacubitril/valsartan was withdrawn in 3 of 21 patients (14.3%) because of dizziness (n = 2) or pruritus (n = 1). After a median follow-up of 12 months (range 1-34 months), NYHA functional class improved significantly from NYHA 3 to NYHA 2 (mean -0.6, p = 0.006) and left ventricular ejection fraction as assessed by echocardiography increased significantly from 26.8 ± 5.4% to 39.2 ± 10% (mean + 12%, CI 95% [8.4-16.4], p = 0.0004). NT-proBNP was significantly reduced (baseline median 2774 pg/ml, range 1441 - 12,982 vs follow-up 1266 pg/ml, range 199-6324, p = 0.009). There was no significant change in creatinine levels (1.18 ± 0.4 vs 1.22 ± 0.4 mg/dl; mean + 0.005 mg/dl, CI 95% [-0.21- 0.12], p = 0.566). In our pilot study we show that sacubitril/valsartan is generally well tolerated in patients with HFrEF and history of cancer. Importantly, even patients with long-standing cardiotoxicity induced heart failure can be treated and up-titrated with sacubitril/valsartan to usual target dosages, leading to improvement in LV function and biomarkers. Larger studies are needed to confirm these findings in cancer patients with cardiotoxicity.
Sections du résumé
BACKGROUND
BACKGROUND
Sacubitril/valsartan has been shown to significantly reduce cardiovascular mortality and hospitalizations due to heart failure in patients with reduced ejection fraction (HFrEF) when compared to enalapril. Data about sacubitril/valsartan in patients with a history of cancer are scarce, as these patients were excluded from the pivotal trial, PARADIGM-HF. The aim of the current study was to assess tolerability of sacubitril/valsartan in patients with a history of cancer.
METHODS
METHODS
We identified 225 patients at our heart failure out-patient unit who fulfilled the indication criteria to receive sacubitril/valsartan. Out of these, 9.3% (n = 21) had a history of histologically confirmed cancer. Oncologic surgery was performed in 16 (76.2%) patients, 11 (52.4%) patients received previous antineoplastic therapy and 9 patients (42.9%) radiation.
RESULTS
RESULTS
Sacubitril/valsartan was withdrawn in 3 of 21 patients (14.3%) because of dizziness (n = 2) or pruritus (n = 1). After a median follow-up of 12 months (range 1-34 months), NYHA functional class improved significantly from NYHA 3 to NYHA 2 (mean -0.6, p = 0.006) and left ventricular ejection fraction as assessed by echocardiography increased significantly from 26.8 ± 5.4% to 39.2 ± 10% (mean + 12%, CI 95% [8.4-16.4], p = 0.0004). NT-proBNP was significantly reduced (baseline median 2774 pg/ml, range 1441 - 12,982 vs follow-up 1266 pg/ml, range 199-6324, p = 0.009). There was no significant change in creatinine levels (1.18 ± 0.4 vs 1.22 ± 0.4 mg/dl; mean + 0.005 mg/dl, CI 95% [-0.21- 0.12], p = 0.566).
CONCLUSIONS
CONCLUSIONS
In our pilot study we show that sacubitril/valsartan is generally well tolerated in patients with HFrEF and history of cancer. Importantly, even patients with long-standing cardiotoxicity induced heart failure can be treated and up-titrated with sacubitril/valsartan to usual target dosages, leading to improvement in LV function and biomarkers. Larger studies are needed to confirm these findings in cancer patients with cardiotoxicity.
Identifiants
pubmed: 34645527
doi: 10.1186/s40959-021-00121-y
pii: 10.1186/s40959-021-00121-y
pmc: PMC8513362
doi:
Types de publication
Journal Article
Langues
eng
Pagination
35Informations de copyright
© 2021. The Author(s).
Références
J Am Coll Cardiol. 2019 Mar 26;73(11):1264-1272
pubmed: 30846338
Cardiooncology. 2020 Nov 5;6(1):24
pubmed: 33292750
J Am Soc Echocardiogr. 2011 Jan;24(1):1-10
pubmed: 21172594
Eur Heart J. 2021 Oct 21;42(40):4194
pubmed: 34520521
Eur Heart J Cardiovasc Imaging. 2013 Aug;14(8):721-40
pubmed: 23847385
Eur Heart J. 2016 Sep 21;37(36):2768-2801
pubmed: 27567406
Eur J Heart Fail. 2020 Sep;22(9):1504-1524
pubmed: 32621569
Eur Heart J Cardiovasc Imaging. 2018 Jun 1;19(6):591-600
pubmed: 29596561
Eur J Pharmacol. 2020 Aug 15;881:173120
pubmed: 32325147
JAMA. 2019 Sep 17;322(11):1085-1095
pubmed: 31475295
Eur J Heart Fail. 2018 May;20(5):879-887
pubmed: 29464808
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015
Eur J Heart Fail. 2020 Nov;22(11):1945-1960
pubmed: 32463967
ESC Heart Fail. 2020 Apr;7(2):763-767
pubmed: 32022485
Circulation. 2015 Jun 2;131(22):1981-8
pubmed: 25948538
J Am Soc Echocardiogr. 2015 Feb;28(2):183-93
pubmed: 25623220
Eur Heart J. 2019 Dec 21;40(48):3889-3897
pubmed: 31761945
SAGE Open Med Case Rep. 2020 Sep 15;8:2050313X20952189
pubmed: 32974024
ESC Heart Fail. 2018 Oct;5(5):956-959
pubmed: 30039930
Cardiovasc Res. 2020 Apr 1;116(5):970-982
pubmed: 31346605
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
J Am Coll Cardiol. 2014 Sep 2;64(9):938-45
pubmed: 25169180
Eur Heart J. 2014 Apr;35(14):932-41
pubmed: 23990596
Cardiovasc Res. 2020 Sep 1;116(11):1820-1834
pubmed: 32683451
Eur J Heart Fail. 2020 Jul;22(7):1230-1238
pubmed: 32202022
Eur J Heart Fail. 2020 Dec;22(12):2272-2289
pubmed: 33094495